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CASE REPORT
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We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects. Indications for GBP
treatment were newly diagnosed epilepsy in one and painful paraesthesiae in the other. Both had no past history of psychiatric
or behavioural disorder. Abnormal behaviour consisted of elevated mood, euphoria, and increased energy in both patients, and
pressure of speech and decreased need for sleep in one of them. These symptoms were transient and fully reversible. One patient
had to discontinue GBP. Behavioural changes were not related to seizure activity. They should be recognized as a possible side
effect of GBP treatment in adults.
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INTRODUCTION
Gabapentin (GBP) is a new antiepileptic drug (AED)
structurally related to γ -aminobutyric acid (GABA).
GBP crosses the blood–brain barrier but is neither
metabolized nor bound to plasma protein and does
not affect serum concentrations of other antiepilep-
tic drugs1. It has been marketed as an anticonvulsant
with ‘ideal’ pharmacokinetic properties, effective in
adults as add-on therapy and monotherapy for epilep-
sies with partial seizures2–7. GBP is also effective as
add-on therapy for children aged >3 years8. Further-
more, GBP is used in the treatment of neuropathic
pain9–11, migraine12, erythromelalgia13, 14 and painful
dysaesthesias in multiple sclerosis15.
In general, GBP is associated with very low toxi-
city and a favourable safety profile16. We report two
patients who exhibited behavioural problems after
moderate doses of GBP.
Case 1
A woman experienced her first generalized tonic–
clonic seizure at the age of 37, although, since the
age of 3 years, she had had attacks with a vague epi-
gastric sensation followed by dizziness. These attacks
occurred at least once or twice a month. Neurologi-
cal examination, birth history, and past medical his-
tory, routine laboratory tests, cerebral computed tomo-
graphy (CCT) scan, and electroencephalogram (EEG)
were normal. She is of normal intelligence and does
not have a past psychiatric history. She is married
and works as a secretary in an office. A diagnosis
of epilepsy with partial seizures with secondary gen-
eralized tonic–clonic seizures was made. We started
GBP monotherapy increasing by 300 mg daily to
a maintenance dose of 600 mg three times daily.
After 5 days of treatment she felt unusually well and
euphoric. Her husband and her colleagues at work
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recognized the mood change. She was compelled to
laugh in inappropriate situations and felt full of en-
ergy. She had no flight of ideas, her speech was not
pressured and reportedly sleep was normal and not
disrupted. The patient herself did not feel unwell, but
she recognized that her inappropriate laughter and gig-
gling impaired her functioning at work. We stopped
GBP after 16 days of treatment, during which time
the patient was seizure free and started with carba-
mazepine (CBZ). Three days later her symptoms re-
solved completely and her seizures have remained
controlled for 2 years with CBZ. No further episodes
of inappropriate behaviour have been reported.
Case 2
A 38-year-old previously healthy female was admit-
ted to hospital because of severe thoracic pain and
fatigue, which developed 2 weeks after laryngitis. A
myocarditis of unknown aetiology was diagnosed. She
was treated with antipyretics and bed rest. Two weeks
later she experienced severe pain in her left arm, shoul-
der and left hemibody, accompanied by unpleasant
paraesthesiae and dizziness. On neurological exam-
ination she had hemi-hypaesthesia on her left side
accompanied with brisk deep tendon reflexes and a
positive Babinski’s sign. There was no past psychiatric
history. Past medical and family history was normal.
Lumbar puncture with CSF analysis revealed intrathe-
cal immunoglobulin M synthesis and positive antibody
titres against chlamydia. A diagnosis of parainfectious
encephalomyelitis was made and a 5-day treatment
course with corticosteroids was initiated. The unpleas-
ant and painful paraesthesiae were treated with GBP.
We increased the dosage gradually by 300 mg a day
to a maintenance dose of 300 mg t.i.d. The painful
paraesthesiae resolved gradually, but a week later she
experienced mood changes with euphoria, inappro-
priate laughter and giggling. Her husband recognized
this mood change. She did not feel uncomfortable,
displayed increased energy and a decreased need for
sleep. Speech was not typically pressured but fast and
difficult to interrupt. She had no flight of ideas and did
not show increased goal-directed activity or grandios-
ity. The mood changes were not severe enough to
cause marked impairment in functioning. Her painful
paraesthesiae improved so she decided to stay on GBP.
The euphoria resolved and her behaviour returned to
baseline within the next 2 weeks without any change
in medication.
DISCUSSION
GBP is a new AED which is used worldwide
for the treatment of epilepsies with partial seizures
in adults and children >3 years, and neuropathic
pain. It is known as a safe drug with desirable
pharmacokinetic properties. The most common side
effects in adults were somnolence, dizziness, fatigue,
nausea, ataxia, and headache5, 6, 16. Several reports of
behavioural side effects of GBP in children have been
published17–21.
Wolf and co-workers17 described three children
with learning disabilities and intractable partial
seizures who became hyperactive and had explo-
sive outbursts consisting of aggressive and opposi-
tional behaviour on GBP. The behavioural problems
were sufficiently severe to require discontinuation of
GBP despite moderately improved seizure control.
Tallian et al.20 reported two children who received
GBP for intractable seizures and who developed in-
tolerable aggressive behaviour requiring dose reduc-
tion or drug discontinuation. Lee et al.18 reported
seven children who received gabapentin (GBP) as
adjunctive medication and subsequently developed
behavioural changes consisting of intensification of
baseline behavioural abnormalities as well as new
behavioural problems. Behaviour which parents con-
sidered most troublesome was, tantrums, aggression
directed toward others, hyperactivity, and defiance. All
behavioural changes were reversible and were man-
aged by dose reduction or discontinuation of GBP.
All children had baseline attention deficit hyperactiv-
ity disorder (ADHD) or developmental delay.
In adults there is only one case report of gabapentin-
induced behavioural change22. This patient was men-
tally retarded and had refractory epilepsy. He re-
ceived GBP in moderate doses and became markedly
disinhibited and over familiar towards female staff
on the ward, making inappropriate sexual remarks
and becoming physically demonstrative. His sleep
pattern was markedly disrupted. His behaviour was
diagnosed as hypomania. It has been speculated23
that the episode was related to forced normalization,
initially described by Landolt24. However, a detailed
description of seizure control and EEG findings were
not reported.
In the present series, patient no. 1 had newly diag-
nosed epilepsy and not chronic epilepsy. She entered
seizure remission at the start of treatment with GBP
and had no seizure activity after introduction of CBZ
monotherapy. Patient no. 2 did not have epilepsy at
all. Therefore we cannot attribute the mood changes
to forced normalization in our patients. The episode
of elevated mood was clearly different from the ha-
bitual mood in both patients and was recognized as
abnormal by their husbands. Severity of symptoms
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did not prompt hospitalization. In patient no. 1, inter-
ference with functioning at work as a secretary was
severe enough to lead to drug withdrawal. The onset
of episodes was related to the start of GBP treatment
and resolved gradually despite continued GBP medi-
cation in patient no. 2. We classified these episodes ac-
cording to DSM-IV (292.84)25 as gabapentin-induced
mood disorder with mild manic features and onset dur-
ing medication.
The gabapentin-induced behavioural changes in
children and the mood changes with hypomanic fea-
tures in adults are both characterized by excessive
activity and impulsive behaviour. The behavioural
changes in children are distinguished by the absence
of elevated or euphoric mood. Characteristically, chil-
dren with chronic epilepsy and static encephalopathy
with behavioural problems (e.g. ADHD) are at risk of
developing intensification of baseline behaviour or de
novo behavioural problems. These side effects in chil-
dren are not unique to GBP and have been reported
with valproate, carbamazepine, clonazepam and phe-
nobarbital26–29.
To date, all previously reported patients with GBP-
induced behavioural changes had difficult to treat
epilepsy. From these observations it is not clear
whether the behavioural disturbances can be attributed
to; (i) forced normalization, (ii) a direct pharmacolog-
ical effect, (iii) the seizures themselves, as for exam-
ple in peri-ictal psychosis30, or (iv) intensification of
baseline behavioural disorder. To our knowledge this
is the first report of GBP-induced mood changes in a
patient with newly diagnosed epilepsy and a patient
with painful paraesthesiae. The behavioural side ef-
fects in these two patients cannot be explained by the
phenomenon of forced normalization or peri-ictal psy-
chosis nor by intensification of an underlying chronic
behavioural or psychiatric disorder. Therefore we con-
clude that the most likely mechanism is a direct phar-
macological effect of GBP. Although the severity of
mood changes in our adult patients has been mild and
self-limiting or reversible, clinicians should recognize
the possibility of adverse behavioural changes, espe-
cially hypomania-like episodes not only in mentally
handicapped children but also in adults during GBP
therapy.
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